English
简体中文
Total: £ 56.28
Published Date: 2025-06-30 | Pages: 74 | Tables: 72 | Medical Care
The global market for Multiple Sclerosis Therapies was valued at US$ 23820 million in the year 2024 and is projected to reach a revised size of US$ 30120 million by 2031, growing at a CAGR of 3.5% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Multiple Sclerosis Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Sclerosis Therapies.
The Multiple Sclerosis Therapies market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Multiple Sclerosis Therapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Multiple Sclerosis Therapies companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
Biogen
Bristol Myers Squibb
Roche
GSK
Merck Group
Novartis
Teva Pharmaceutical Industries
Sanofi
Segment by Type
Acute Attack Treatment
Disease Remission Treatment
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Multiple Sclerosis Therapies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Multiple Sclerosis Therapies Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Acute Attack Treatment
1.2.3 Disease Remission Treatment
1.3 Market by Application
1.3.1 Global Multiple Sclerosis Therapies Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Multiple Sclerosis Therapies Market Perspective (2020-2031)
2.2 Global Multiple Sclerosis Therapies Growth Trends by Region
2.2.1 Global Multiple Sclerosis Therapies Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Multiple Sclerosis Therapies Historic Market Size by Region (2020-2025)
2.2.3 Multiple Sclerosis Therapies Forecasted Market Size by Region (2026-2031)
2.3 Multiple Sclerosis Therapies Market Dynamics
2.3.1 Multiple Sclerosis Therapies Industry Trends
2.3.2 Multiple Sclerosis Therapies Market Drivers
2.3.3 Multiple Sclerosis Therapies Market Challenges
2.3.4 Multiple Sclerosis Therapies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Multiple Sclerosis Therapies Players by Revenue
3.1.1 Global Top Multiple Sclerosis Therapies Players by Revenue (2020-2025)
3.1.2 Global Multiple Sclerosis Therapies Revenue Market Share by Players (2020-2025)
3.2 Global Multiple Sclerosis Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Multiple Sclerosis Therapies Revenue
3.4 Global Multiple Sclerosis Therapies Market Concentration Ratio
3.4.1 Global Multiple Sclerosis Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Multiple Sclerosis Therapies Revenue in 2024
3.5 Global Key Players of Multiple Sclerosis Therapies Head office and Area Served
3.6 Global Key Players of Multiple Sclerosis Therapies, Product and Application
3.7 Global Key Players of Multiple Sclerosis Therapies, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Multiple Sclerosis Therapies Breakdown Data by Type
4.1 Global Multiple Sclerosis Therapies Historic Market Size by Type (2020-2025)
4.2 Global Multiple Sclerosis Therapies Forecasted Market Size by Type (2026-2031)
5 Multiple Sclerosis Therapies Breakdown Data by Application
5.1 Global Multiple Sclerosis Therapies Historic Market Size by Application (2020-2025)
5.2 Global Multiple Sclerosis Therapies Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Multiple Sclerosis Therapies Market Size (2020-2031)
6.2 North America Multiple Sclerosis Therapies Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Multiple Sclerosis Therapies Market Size by Country (2020-2025)
6.4 North America Multiple Sclerosis Therapies Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Multiple Sclerosis Therapies Market Size (2020-2031)
7.2 Europe Multiple Sclerosis Therapies Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Multiple Sclerosis Therapies Market Size by Country (2020-2025)
7.4 Europe Multiple Sclerosis Therapies Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Multiple Sclerosis Therapies Market Size (2020-2031)
8.2 Asia-Pacific Multiple Sclerosis Therapies Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Multiple Sclerosis Therapies Market Size by Region (2020-2025)
8.4 Asia-Pacific Multiple Sclerosis Therapies Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Multiple Sclerosis Therapies Market Size (2020-2031)
9.2 Latin America Multiple Sclerosis Therapies Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Multiple Sclerosis Therapies Market Size by Country (2020-2025)
9.4 Latin America Multiple Sclerosis Therapies Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Multiple Sclerosis Therapies Market Size (2020-2031)
10.2 Middle East & Africa Multiple Sclerosis Therapies Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Multiple Sclerosis Therapies Market Size by Country (2020-2025)
10.4 Middle East & Africa Multiple Sclerosis Therapies Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Details
11.1.2 Bayer Business Overview
11.1.3 Bayer Multiple Sclerosis Therapies Introduction
11.1.4 Bayer Revenue in Multiple Sclerosis Therapies Business (2020-2025)
11.1.5 Bayer Recent Development
11.2 Biogen
11.2.1 Biogen Company Details
11.2.2 Biogen Business Overview
11.2.3 Biogen Multiple Sclerosis Therapies Introduction
11.2.4 Biogen Revenue in Multiple Sclerosis Therapies Business (2020-2025)
11.2.5 Biogen Recent Development
11.3 Bristol Myers Squibb
11.3.1 Bristol Myers Squibb Company Details
11.3.2 Bristol Myers Squibb Business Overview
11.3.3 Bristol Myers Squibb Multiple Sclerosis Therapies Introduction
11.3.4 Bristol Myers Squibb Revenue in Multiple Sclerosis Therapies Business (2020-2025)
11.3.5 Bristol Myers Squibb Recent Development
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Multiple Sclerosis Therapies Introduction
11.4.4 Roche Revenue in Multiple Sclerosis Therapies Business (2020-2025)
11.4.5 Roche Recent Development
11.5 GSK
11.5.1 GSK Company Details
11.5.2 GSK Business Overview
11.5.3 GSK Multiple Sclerosis Therapies Introduction
11.5.4 GSK Revenue in Multiple Sclerosis Therapies Business (2020-2025)
11.5.5 GSK Recent Development
11.6 Merck Group
11.6.1 Merck Group Company Details
11.6.2 Merck Group Business Overview
11.6.3 Merck Group Multiple Sclerosis Therapies Introduction
11.6.4 Merck Group Revenue in Multiple Sclerosis Therapies Business (2020-2025)
11.6.5 Merck Group Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Multiple Sclerosis Therapies Introduction
11.7.4 Novartis Revenue in Multiple Sclerosis Therapies Business (2020-2025)
11.7.5 Novartis Recent Development
11.8 Teva Pharmaceutical Industries
11.8.1 Teva Pharmaceutical Industries Company Details
11.8.2 Teva Pharmaceutical Industries Business Overview
11.8.3 Teva Pharmaceutical Industries Multiple Sclerosis Therapies Introduction
11.8.4 Teva Pharmaceutical Industries Revenue in Multiple Sclerosis Therapies Business (2020-2025)
11.8.5 Teva Pharmaceutical Industries Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Details
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Multiple Sclerosis Therapies Introduction
11.9.4 Sanofi Revenue in Multiple Sclerosis Therapies Business (2020-2025)
11.9.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Multiple Sclerosis Therapies Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Acute Attack Treatment
Table 3. Key Players of Disease Remission Treatment
Table 4. Global Multiple Sclerosis Therapies Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Multiple Sclerosis Therapies Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Multiple Sclerosis Therapies Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Multiple Sclerosis Therapies Market Share by Region (2020-2025)
Table 8. Global Multiple Sclerosis Therapies Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Multiple Sclerosis Therapies Market Share by Region (2026-2031)
Table 10. Multiple Sclerosis Therapies Market Trends
Table 11. Multiple Sclerosis Therapies Market Drivers
Table 12. Multiple Sclerosis Therapies Market Challenges
Table 13. Multiple Sclerosis Therapies Market Restraints
Table 14. Global Multiple Sclerosis Therapies Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Multiple Sclerosis Therapies Market Share by Players (2020-2025)
Table 16. Global Top Multiple Sclerosis Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Sclerosis Therapies as of 2024)
Table 17. Ranking of Global Top Multiple Sclerosis Therapies Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Multiple Sclerosis Therapies Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Multiple Sclerosis Therapies, Headquarters and Area Served
Table 20. Global Key Players of Multiple Sclerosis Therapies, Product and Application
Table 21. Global Key Players of Multiple Sclerosis Therapies, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Multiple Sclerosis Therapies Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Multiple Sclerosis Therapies Revenue Market Share by Type (2020-2025)
Table 25. Global Multiple Sclerosis Therapies Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Multiple Sclerosis Therapies Revenue Market Share by Type (2026-2031)
Table 27. Global Multiple Sclerosis Therapies Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Multiple Sclerosis Therapies Revenue Market Share by Application (2020-2025)
Table 29. Global Multiple Sclerosis Therapies Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Multiple Sclerosis Therapies Revenue Market Share by Application (2026-2031)
Table 31. North America Multiple Sclerosis Therapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Multiple Sclerosis Therapies Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Multiple Sclerosis Therapies Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Multiple Sclerosis Therapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Multiple Sclerosis Therapies Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Multiple Sclerosis Therapies Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Multiple Sclerosis Therapies Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Multiple Sclerosis Therapies Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Multiple Sclerosis Therapies Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Multiple Sclerosis Therapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Multiple Sclerosis Therapies Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Multiple Sclerosis Therapies Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Multiple Sclerosis Therapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Multiple Sclerosis Therapies Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Multiple Sclerosis Therapies Market Size by Country (2026-2031) & (US$ Million)
Table 46. Bayer Company Details
Table 47. Bayer Business Overview
Table 48. Bayer Multiple Sclerosis Therapies Product
Table 49. Bayer Revenue in Multiple Sclerosis Therapies Business (2020-2025) & (US$ Million)
Table 50. Bayer Recent Development
Table 51. Biogen Company Details
Table 52. Biogen Business Overview
Table 53. Biogen Multiple Sclerosis Therapies Product
Table 54. Biogen Revenue in Multiple Sclerosis Therapies Business (2020-2025) & (US$ Million)
Table 55. Biogen Recent Development
Table 56. Bristol Myers Squibb Company Details
Table 57. Bristol Myers Squibb Business Overview
Table 58. Bristol Myers Squibb Multiple Sclerosis Therapies Product
Table 59. Bristol Myers Squibb Revenue in Multiple Sclerosis Therapies Business (2020-2025) & (US$ Million)
Table 60. Bristol Myers Squibb Recent Development
Table 61. Roche Company Details
Table 62. Roche Business Overview
Table 63. Roche Multiple Sclerosis Therapies Product
Table 64. Roche Revenue in Multiple Sclerosis Therapies Business (2020-2025) & (US$ Million)
Table 65. Roche Recent Development
Table 66. GSK Company Details
Table 67. GSK Business Overview
Table 68. GSK Multiple Sclerosis Therapies Product
Table 69. GSK Revenue in Multiple Sclerosis Therapies Business (2020-2025) & (US$ Million)
Table 70. GSK Recent Development
Table 71. Merck Group Company Details
Table 72. Merck Group Business Overview
Table 73. Merck Group Multiple Sclerosis Therapies Product
Table 74. Merck Group Revenue in Multiple Sclerosis Therapies Business (2020-2025) & (US$ Million)
Table 75. Merck Group Recent Development
Table 76. Novartis Company Details
Table 77. Novartis Business Overview
Table 78. Novartis Multiple Sclerosis Therapies Product
Table 79. Novartis Revenue in Multiple Sclerosis Therapies Business (2020-2025) & (US$ Million)
Table 80. Novartis Recent Development
Table 81. Teva Pharmaceutical Industries Company Details
Table 82. Teva Pharmaceutical Industries Business Overview
Table 83. Teva Pharmaceutical Industries Multiple Sclerosis Therapies Product
Table 84. Teva Pharmaceutical Industries Revenue in Multiple Sclerosis Therapies Business (2020-2025) & (US$ Million)
Table 85. Teva Pharmaceutical Industries Recent Development
Table 86. Sanofi Company Details
Table 87. Sanofi Business Overview
Table 88. Sanofi Multiple Sclerosis Therapies Product
Table 89. Sanofi Revenue in Multiple Sclerosis Therapies Business (2020-2025) & (US$ Million)
Table 90. Sanofi Recent Development
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources
Table 94. Authors List of This Report
List of Figures
Figure 1. Multiple Sclerosis Therapies Picture
Figure 2. Global Multiple Sclerosis Therapies Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Multiple Sclerosis Therapies Market Share by Type: 2024 VS 2031
Figure 4. Acute Attack Treatment Features
Figure 5. Disease Remission Treatment Features
Figure 6. Global Multiple Sclerosis Therapies Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Multiple Sclerosis Therapies Market Share by Application: 2024 VS 2031
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Multiple Sclerosis Therapies Report Years Considered
Figure 12. Global Multiple Sclerosis Therapies Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Multiple Sclerosis Therapies Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Multiple Sclerosis Therapies Market Share by Region: 2024 VS 2031
Figure 15. Global Multiple Sclerosis Therapies Market Share by Players in 2024
Figure 16. Global Top Multiple Sclerosis Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Sclerosis Therapies as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Multiple Sclerosis Therapies Revenue in 2024
Figure 18. North America Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Multiple Sclerosis Therapies Market Share by Country (2020-2031)
Figure 20. United States Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Multiple Sclerosis Therapies Market Share by Country (2020-2031)
Figure 24. Germany Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Multiple Sclerosis Therapies Market Share by Region (2020-2031)
Figure 32. China Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Multiple Sclerosis Therapies Market Share by Country (2020-2031)
Figure 40. Mexico Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Multiple Sclerosis Therapies Market Share by Country (2020-2031)
Figure 44. Turkey Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Multiple Sclerosis Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Bayer Revenue Growth Rate in Multiple Sclerosis Therapies Business (2020-2025)
Figure 48. Biogen Revenue Growth Rate in Multiple Sclerosis Therapies Business (2020-2025)
Figure 49. Bristol Myers Squibb Revenue Growth Rate in Multiple Sclerosis Therapies Business (2020-2025)
Figure 50. Roche Revenue Growth Rate in Multiple Sclerosis Therapies Business (2020-2025)
Figure 51. GSK Revenue Growth Rate in Multiple Sclerosis Therapies Business (2020-2025)
Figure 52. Merck Group Revenue Growth Rate in Multiple Sclerosis Therapies Business (2020-2025)
Figure 53. Novartis Revenue Growth Rate in Multiple Sclerosis Therapies Business (2020-2025)
Figure 54. Teva Pharmaceutical Industries Revenue Growth Rate in Multiple Sclerosis Therapies Business (2020-2025)
Figure 55. Sanofi Revenue Growth Rate in Multiple Sclerosis Therapies Business (2020-2025)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
